Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study
Steven R. Alberts(Northwestern University), John H. Donohue(American Cancer Society), Daniel J. Sargent(Mayo Clinic in Arizona), Kendrith M. Rowland(Columbus Community Clinical Oncology Program), William L. Horvath(Columbus Community Clinical Oncology Program), Suresh Nair(Lehigh Valley Hospital-Pocono), Richard M. Goldberg(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ralph Levitt(Columbus Community Clinical Oncology Program), Michelle R. Mahoney(Columbus Community Clinical Oncology Program), Shaker R. Dakhil(Cancer Center of Kansas), William C. Sternfeld(Columbus Community Clinical Oncology Program)
Cited by 541
Related Papers
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
|New England Journal of Medicine|2001|992